You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArtemether
Accession NumberDB06697
TypeSmall Molecule
GroupsApproved
DescriptionArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Structure
Thumb
Synonyms
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
Artemetero
Artemetherum
Artemisininelactol methyl ether
beta-Artemether
beta-Dihydroartemisinin methyl ether
Dihydroartemisinin methyl ether
Dihydroqinghaosu methyl ether
Methyl-dihydroartemisinine
SM-224
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
CoartemNovartis Pharmaceuticals Corporation
SaltsNot Available
Categories
UNIIC7D6T3H22J
CAS number71963-77-4
WeightAverage: 298.3746
Monoisotopic: 298.178023942
Chemical FormulaC16H26O5
InChI KeySXYIRMFQILZOAM-HVNFFKDJSA-N
InChI
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecane
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[[email protected]](OC)[C@@H]2C)O4
Pharmacology
IndicationArtemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
Structured Indications
PharmacodynamicsIn the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Mechanism of actionInvolves an interaction with ferriprotoporphyrin IX (“heme”), or ferrous ions, in the acidic parasite food vacuole, which results in the generation of cytotoxic radical species. The generally accepted mechanism of action of peroxide antimalarials involves interaction of the peroxide-containing drug with heme, a hemoglobin degradation byproduct, derived from proteolysis of hemoglobin. This interaction is believed to result in the formation of a range of potentially toxic oxygen and carbon-centered radicals.
Related Articles
AbsorptionFood increases absorption.
Volume of distributionNot Available
Protein bindingArtemether and lumefantrine are both highly bound to human serum proteins in vitro (95.4% and 99.7%, respectively). Dihydroartemisinin is also bound to human serum proteins (47% to 76%).
Metabolism

Rapidly metablized to its active metabolite, dihydroartemisinin.

SubstrateEnzymesProduct
Artemether
Dihydroartemisinin (DHA)Details
Artemether
Not Available
9,10-dihydrodeoxy-artemsininDetails
Artemether
Not Available
Alpha-dihydroartemisininDetails
Artemether
Not Available
DeoxyartemsininDetails
Artemether
Not Available
Deoxydihydro-artemisininDetails
Route of eliminationNot Available
Half lifeArtemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr
ClearanceNot Available
ToxicityAnimal studies on acute toxicity show that the LD50 of Artemether in mice is a single i.g. administration of 895mg/kg and a single i.m. injection of 296mg/kg dose; in rats, the LD50 is a single i.m. injection of 597mg/kg dose.
Affected organisms
  • Plasmodium
Pathways
PathwayCategorySMPDB ID
Artemether Metabolism PathwayDrug metabolismSMP00651
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Artemether.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when Artemether is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AbirateroneThe serum concentration of Artemether can be increased when it is combined with Abiraterone.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Artemether.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Artemether.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Artemether.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Artemether.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Artemether.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Artemether.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Artemether.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Artemether.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Artemether.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Artemether.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Artemether.Approved, Withdrawn
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Artemether.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Amlodipine.Approved
AmodiaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Artemether.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Artemether.Approved, Illicit
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Artemether.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Artemether is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Artemether.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Artemether.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Artemether.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AprepitantThe serum concentration of Artemether can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Artemether.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved, Investigational
ArmodafinilThe metabolism of Artemether can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
ArtemisininThe risk or severity of adverse effects can be increased when Artemether is combined with Artemisinin.Investigational
ArtesunateThe risk or severity of adverse effects can be increased when Artemether is combined with Artesunate.Approved
AsenapineAsenapine may increase the QTc-prolonging activities of Artemether.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Artemether.Approved, Withdrawn
AtazanavirThe metabolism of Artemether can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Artemether.Approved
AtovaquoneThe risk or severity of adverse effects can be increased when Artemether is combined with Atovaquone.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Artemether.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Artemether is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Artemether.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Artemether.Approved
BenidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Benidipine.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Artemether.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Artemether.Approved
BepridilThe risk or severity of adverse effects can be increased when Artemether is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Artemether can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Artemether is combined with Betulinic Acid.Investigational
BexaroteneThe serum concentration of Artemether can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Artemether.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Artemether.Investigational
BoceprevirThe metabolism of Artemether can be decreased when combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
BosentanThe serum concentration of Artemether can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Artemether.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Artemether.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Artemether.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Artemether.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Artemether.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Artemether can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Artemether.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Artemether.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Artemether.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Artemether.Approved
CaiThe risk or severity of adverse effects can be increased when Artemether is combined with Cai.Investigational
CapecitabineThe metabolism of Artemether can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Artemether.Approved
CarbamazepineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Artemether.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Artemether.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Artemether.Approved, Investigational
CelecoxibThe metabolism of Artemether can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Artemether.Approved, Vet Approved
CeritinibThe serum concentration of Artemether can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Artemether.Approved
ChloramphenicolThe metabolism of Artemether can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Artemether.Approved, Illicit
ChloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Artemether.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Artemether.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.Approved
CholecalciferolThe metabolism of Artemether can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Cilnidipine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Artemether.Approved
CimetidineThe metabolism of Artemether can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Artemether can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Cinnarizine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Artemether.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Artemether.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Artemether.Approved
ClemastineThe metabolism of Artemether can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Clevidipine.Approved
ClobazamThe metabolism of Artemether can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Artemether.Approved
ClopidogrelThe metabolism of Artemether can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Artemether can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Artemether.Approved
CobicistatThe serum concentration of Artemether can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Artemether can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.Approved, Illicit
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Artemether.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Artemether.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Artemether.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Artemether.Approved
DapsoneThe risk or severity of adverse effects can be increased when Artemether is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Artemether can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Darodipine.Experimental
DarunavirThe serum concentration of Artemether can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Artemether.Approved
DasatinibThe serum concentration of Artemether can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Artemether.Approved
DeferasiroxThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Artemether.Approved
DelavirdineThe metabolism of Artemether can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Artemether.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Artemether.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Artemether.Approved
DexamethasoneThe serum concentration of Artemether can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Artemether.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Artemether.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Artemether.Approved
DidanosineDidanosine can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Artemether.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Artemether.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Artemether.Approved
DihydroartemisininThe risk or severity of adverse effects can be increased when Artemether is combined with Dihydroartemisinin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.Approved, Illicit
DihydroergotamineThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Artemether is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Artemether.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Artemether.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Artemether.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Artemether.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Artemether.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Artemether.Approved
DotarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Dotarizine.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Artemether.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Artemether.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Artemether.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Artemether.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Artemether is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the QTc-prolonging activities of Artemether.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Artemether.Approved
DuloxetineThe metabolism of Artemether can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Artemether.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Artemether.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Artemether.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Artemether.Investigational
EnzalutamideThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.Approved
EperisoneThe risk or severity of adverse effects can be increased when Artemether is combined with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Artemether.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Artemether.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Artemether.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Artemether can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Artemether.Investigational
EsomeprazoleThe metabolism of Artemether can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Artemether.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Artemether.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Artemether.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Artemether.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Artemether.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Artemether.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Artemether.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Artemether.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Artemether.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Artemether.Approved
FelodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Artemether is combined with Fendiline.Withdrawn
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Artemether.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Artemether.Approved, Withdrawn
FloxuridineThe metabolism of Artemether can be decreased when combined with Floxuridine.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Artemether.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Flunarizine.Approved
FluorouracilThe metabolism of Artemether can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Artemether.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Artemether.Approved
FluvoxamineThe metabolism of Artemether can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
FosamprenavirThe metabolism of Artemether can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Artemether can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Artemether.Approved
FosphenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.Approved
Fusidic AcidThe serum concentration of Artemether can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Artemether is combined with Gabapentin.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Artemether.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Artemether.Approved
GallopamilThe risk or severity of adverse effects can be increased when Artemether is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Artemether.Approved, Investigational
GemfibrozilThe metabolism of Artemether can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Artemether.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Artemether.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Artemether.Approved, Investigational
HalofantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Halofantrine.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Artemether.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Artemether.Approved, Vet Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Artemether.Withdrawn
HistrelinHistrelin may increase the QTc-prolonging activities of Artemether.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Artemether.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Artemether.Approved, Illicit
HydroxychloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Artemether.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Artemether.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Artemether.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Artemether.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Artemether.Approved
IdelalisibThe serum concentration of Artemether can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the QTc-prolonging activities of Artemether.Approved
ImatinibThe metabolism of Artemether can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Artemether.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Artemether.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Artemether.Approved
IndinavirThe metabolism of Artemether can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.Approved
IrbesartanThe metabolism of Artemether can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Artemether can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
IsoniazidThe metabolism of Artemether can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Artemether.Approved
ItraconazoleThe metabolism of Artemether can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Artemether.Approved
IvacaftorThe serum concentration of Artemether can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Artemether.Approved
KetoconazoleThe metabolism of Artemether can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Artemether.Approved
LacidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Artemether is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LeflunomideThe metabolism of Artemether can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Artemether.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Artemether.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Artemether.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Artemether.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Artemether.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Artemether.Approved
LithiumLithium may increase the QTc-prolonging activities of Artemether.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Artemether.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Artemether.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Artemether.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Artemether.Approved
LorcaserinThe metabolism of Artemether can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Artemether.Approved
LovastatinThe metabolism of Artemether can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Artemether can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Lumacaftor resulting in a loss in efficacy.Approved
LumefantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Lumefantrine.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Artemether.Investigational
Magnesium SulfateThe risk or severity of adverse effects can be increased when Artemether is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Manidipine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Artemether.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Artemether is combined with Mefloquine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Artemether.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Artemether.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Artemether.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Artemether.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Artemether.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Artemether.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Artemether.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Artemether.Approved, Vet Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Artemether.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Artemether.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Artemether.Approved, Illicit, Withdrawn
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
MetoprololThe metabolism of Artemether can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Artemether.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Artemether.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Artemether.Approved
MibefradilThe risk or severity of adverse effects can be increased when Artemether is combined with Mibefradil.Withdrawn
MifepristoneMifepristone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Artemether.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Artemether.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Artemether.Approved
MitotaneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy.Approved
MizoribineThe risk or severity of adverse effects can be increased when Artemether is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Artemether.Approved
ModafinilThe serum concentration of Artemether can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Artemether.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Artemether.Approved, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Artemether.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Artemether.Approved, Investigational
NafcillinThe serum concentration of Artemether can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Artemether is combined with Naftopidil.Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Artemether.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved, Investigational
NefazodoneThe metabolism of Artemether can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Artemether can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Artemether can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Artemether can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Artemether.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Artemether.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Artemether.Approved
NifedipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niguldipine.Experimental
NilotinibNilotinib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Artemether.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Artemether.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Artemether.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Artemether.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Artemether.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Artemether.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Artemether.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Artemether.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
OlaparibThe metabolism of Artemether can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Artemether.Approved
OmeprazoleThe metabolism of Artemether can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Artemether.Approved
OsimertinibThe serum concentration of Artemether can be increased when it is combined with Osimertinib.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Artemether.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Artemether.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
PalbociclibThe serum concentration of Artemether can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the QTc-prolonging activities of Artemether.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Artemether.Approved, Investigational
PanobinostatThe serum concentration of Artemether can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Artemether can be decreased when combined with Pantoprazole.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Artemether.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Artemether.Approved
Peginterferon alfa-2bThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Artemether.Approved
PentobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Vet Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Artemether.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Artemether.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Artemether is combined with Perhexiline.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Artemether.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Artemether.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Artemether.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Artemether.Approved, Withdrawn
PhenobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.Approved
PhenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenytoin resulting in a loss in efficacy.Approved, Vet Approved
PimozideArtemether may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Artemether is combined with Pinaverium.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Artemether.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Artemether.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Artemether.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Artemether.Approved
PosaconazoleThe metabolism of Artemether can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Artemether is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Artemether is combined with Prenylamine.Withdrawn
PrimaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Primaquine.Approved
PrimidoneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Primidone resulting in a loss in efficacy.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Artemether.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.Approved, Vet Approved
ProguanilThe risk or severity of adverse effects can be increased when Artemether is combined with Proguanil.Approved
PromazinePromazine may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Artemether.Approved
PropafenoneThe serum concentration of Artemether can be increased when it is combined with Propafenone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Artemether.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Artemether.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Artemether.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Artemether.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Artemether.Approved
PyrimethamineThe risk or severity of adverse effects can be increased when Artemether is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe risk or severity of adverse effects can be increased when Artemether is combined with Pyronaridine.Investigational
QuazepamThe serum concentration of Artemether can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may increase the QTc-prolonging activities of Artemether.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinacrine.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Artemether.Approved
QuinineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Artemether is combined with Radicicol.Experimental
RanitidineThe metabolism of Ranitidine can be decreased when combined with Artemether.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Artemether.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Artemether.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Artemether.Investigational
RifabutinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifabutin resulting in a loss in efficacy.Approved
RifampicinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifapentineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifapentine resulting in a loss in efficacy.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Artemether.Approved
RisedronateThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
RitonavirThe metabolism of Artemether can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Artemether can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Artemether can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Artemether.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Artemether.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Artemether.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Artemether.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Artemether.Approved
SecobarbitalThe metabolism of Artemether can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Artemether.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Artemether.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SildenafilThe metabolism of Artemether can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Artemether can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Artemether can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Artemether.Approved
SinefunginThe risk or severity of adverse effects can be increased when Artemether is combined with Sinefungin.Experimental
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Artemether.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Artemether.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Artemether.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Artemether.Experimental
St. John's WortThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.Nutraceutical
StiripentolThe serum concentration of Artemether can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe metabolism of Artemether can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfadoxine.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Artemether.Approved
SulfametopyrazineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Artemether.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Artemether.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Artemether.Approved, Investigational
tafenoquineThe risk or severity of adverse effects can be increased when Artemether is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Artemether.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Artemether.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Artemether.Investigational, Withdrawn
TelaprevirThe metabolism of Artemether can be decreased when combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Artemether.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Artemether.Approved
TerbinafineThe metabolism of Artemether can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Artemether.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Artemether.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Artemether.Investigational
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Artemether.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Artemether.Approved
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Artemether.Withdrawn
ThioridazineThioridazine may increase the QTc-prolonging activities of Artemether.Approved
ThiotepaThe metabolism of Artemether can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Artemether.Approved
TicagrelorThe metabolism of Artemether can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Artemether can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Artemether.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Artemether.Approved
TipranavirThe metabolism of Artemether can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Artemether.Approved
TocilizumabThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Artemether can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Artemether is combined with Tolfenamic Acid.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TopiramateThe metabolism of Artemether can be decreased when combined with Topiramate.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Artemether.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Artemether can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Artemether.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.Approved, Vet Approved
TrimethoprimThe risk or severity of adverse effects can be increased when Artemether is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Artemether.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Artemether.Approved, Vet Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Artemether.Approved
Valproic AcidThe metabolism of Artemether can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Artemether can be decreased when combined with Valsartan.Approved, Investigational
VandetanibVandetanib may increase the QTc-prolonging activities of Artemether.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Artemether.Approved
VemurafenibArtemether may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Artemether.Approved
VerapamilThe risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Artemether.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Artemether.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Artemether.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Artemether.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Artemether is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Artemether can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Artemether.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Artemether.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Artemether.Approved, Vet Approved
ZafirlukastThe metabolism of Artemether can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Artemether.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Artemether is combined with Ziconotide.Approved
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Artemether.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Artemether.Approved
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Artemether.Approved, Investigational
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of artemether and lumefantrine.
References
Synthesis Reference
  1. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. Pubmed
General References
  1. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5. [PubMed:19818172 ]
  2. Mutabingwa TK, Adam I: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169. [PubMed:23409819 ]
  3. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. [PubMed:8053018 ]
External Links
ATC CodesP01BE02P01BF01
AHFS Codes
  • 8:30.08
PDB EntriesNot Available
FDA labelDownload (1.73 MB)
MSDSDownload (566 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9012
Blood Brain Barrier+0.9393
Caco-2 permeable+0.7876
P-glycoprotein substrateSubstrate0.6031
P-glycoprotein inhibitor IInhibitor0.8918
P-glycoprotein inhibitor IINon-inhibitor0.7056
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8665
CYP450 2D6 substrateSubstrate0.5341
CYP450 3A4 substrateSubstrate0.7023
CYP450 1A2 substrateInhibitor0.6829
CYP450 2C9 inhibitorNon-inhibitor0.9413
CYP450 2D6 inhibitorNon-inhibitor0.9474
CYP450 2C19 inhibitorNon-inhibitor0.8733
CYP450 3A4 inhibitorNon-inhibitor0.9434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9672
Ames testNon AMES toxic0.7285
CarcinogenicityNon-carcinogens0.9179
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.2114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point86-90Not Available
water solubilityInsoluble # http://www.rxlist.com/coartem-drug.htm
logP3.53AVERY,MA ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP3.02ALOGPS
logP3.48ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability32.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassSesquiterpenoids
Direct ParentArtemisinins
Alternative Parents
Substituents
  • Artemisinin skeleton
  • Oxepane
  • 1,2,4-trioxane
  • Oxane
  • Dialkyl peroxide
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on May 05, 2010 12:03 / Updated on August 17, 2016 12:24